Medical application of hydrogen for preventing or treating psoriasis
Hydrogen gas at 65% concentration treats psoriasis by reducing oxidative stress and inflammation, addressing the limitations of current treatments by effectively downregulating pro-inflammatory cytokines and NF-κB activation.
Patent Information
- Application Number
- CN202310667371.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-06
- Publication Date
- 2024-12-06
AI Technical Summary
Current treatments for psoriasis are mostly topical and systemic, but they are not curative and have significant side effects, and there is a need for a safer and more effective treatment.
Hydrogen gas, specifically at a concentration of 65%, is used to treat psoriasis by reducing oxidative stress and inflammation through inhalation, inhibiting pro-inflammatory cytokines, and downregulating the NF-κB signaling pathway.
Hydrogen gas effectively reduces psoriasis symptoms by decreasing ROS and MDA levels, downregulating pro-inflammatory cytokines, and inhibiting NF-κB activation, showing high biosafety with no toxic side effects.
Smart Images

Figure CN119074760A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and more specifically to the application of hydrogen in the preparation of psoriasis prevention and treatment products. More specifically, it is a new clinical application of hydrogen in the treatment of silver blood disease. Technical Background
[0002] In recent years, with the acceleration of industrialization, urbanization and aging in my country, the prevalence of various chronic inflammatory skin diseases has shown a trend of sustained rapid growth. Psoriasis is one of the most common chronic inflammatory skin diseases in clinical practice, with an incidence rate of about 0.1%-2.9% in people of all races worldwide. A large-scale epidemiological survey in my country in 1984 suggested that the overall national prevalence rate was about 0.123%. There is no large-scale epidemiological survey data in recent years, but with the development of social economy, people's pace of life has intensified, especially the life pressure of young and middle-aged people has increased, and the prevalence of psoriasis in my country has shown a trend of increasing year by year. Zhang Jianzhong et al. investigated six cities in 2007-2008 and found that the prevalence of psoriasis among residents rose to 0.47%.
[0003] Psoriasis has clinical characteristics such as recurrent attacks, stubborn rashes, and unbearable itching. Patients often suffer from psychological disorders such as depression, anxiety, social maladjustment, and even suicidal tendencies to varying degrees, which seriously affects the quality of life of patients. [3] At the same time, psoriasis is often accompanied by multiple complications such as hypertension, diabetes, and metabolic syndrome. The mortality rate of young patients and those with severe conditions is significantly higher than that of healthy people. Psoriasis not only causes great physical and mental pain and economic burden to patients and their families, but also brings great work challenges to medical staff. It has become one of the major diseases that endangers people's health and quality of life and hinders economic and social development.
[0004] The current treatment for psoriasis is mostly topical medication. The most commonly used drugs are hormones, followed by vitamin D3 derivatives such as calcipotriol, calcipotriol or tacalcitol. Calcineurin inhibitors, sulfur emulsion exfoliants and moisturizers are also used, but topical medication cannot cure it fundamentally. For systemic psoriasis with more severe symptoms, systemic treatment is required, such as oral retinoic acid medication, but long-term use has great toxic side effects and is accompanied by liver and kidney damage. Patients' liver function and blood lipids should be checked regularly.
[0005] Therefore, there is an urgent need to research and develop new, safe and effective treatments for psoriasis. Summary of the invention
[0006] The purpose of the present invention is to provide a new use of hydrogen, specifically the medical use of hydrogen for preventing or treating psoriasis.
[0007] Specifically, hydrogen is used as a drug for preventing or treating psoriasis.
[0008] The hydrogen gas exerts a preventive or therapeutic effect through breathing;
[0009] The hydrogen concentration is 65%.
[0010] The hydrogen of the present invention is used for the medical use of preventing or treating psoriasis. It was found through animal models (mouse experiments) that hydrogen can effectively improve the skin lesions of psoriasis mice, and the higher the concentration (65%), the more obvious the improvement of the mouse skin condition. The expression of pro-inflammatory cytokines in the skin lesions was detected, and it was found that hydrogen intervention can significantly downregulate the pro-inflammatory cytokines TNF-α, IL-22, IL-17A and IL-17F, and can significantly downregulate the expression and phosphorylation of p65 and IKBα (NF-κB signaling pathway) in psoriasis lesions. This shows that hydrogen may reduce IL-23-induced inflammation by inhibiting the activation of NF-κB, and further reduce the psoriasis-like lesions caused by IL-23. At the same time, hydrogen treatment restored the activity of peroxisome proliferator-activated receptor-γ coactivator (PGC1)-α in the psoriasis model, thereby reducing the ROS and MDA levels (oxidative damage) and inflammatory response induced by TNF-α, as well as IL-17-induced keratinocyte proliferation.
[0011] Clinical cell models also found that 65% hydrogen intervention reduced the levels of ROS and malondialdehyde (MDA, lipid peroxidation) in patients with psoriasis, reduced the production of proinflammatory factors and oxidative damage, and was beneficial to reducing the cell proliferation, oxidative stress and inflammatory damage levels of keratinocytes in patients with psoriasis, thereby producing a therapeutic effect on psoriasis.
[0012] At the same time, hydrogen has a high degree of biosafety. Its safety is mainly based on the following three aspects. First, more than 70 years of hydrogen diving research by international diving medical institutions has proved that high-pressure hydrogen has no toxic side effects on the human body. Second, intestinal flora research has found that Escherichia coli bacteria in the large intestine can produce hydrogen. Some scholars have proposed that the protective effect of acarbose on the heart may be closely related to its promotion of hydrogen production in the large intestine. Third, with the promotion of hydrogen in clinical research, there is no evidence to date that it is harmful to the human body. At present, hydrogen has been listed as a food additive in many countries such as China, Japan, and the European Union, so its biosafety is beyond doubt.
[0013] The present invention opens up a new use for hydrogen, provides a new intervention method for the clinical treatment and preventive health care of psoriasis, and has good clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 Hydrogen inhibits oxidative stress, inflammatory response, and cell proliferation in keratinocytes isolated from patients with psoriasis
[0015] Figure 2 , hydrogen inhalation can alleviate IL-23-induced psoriasis-like lesions in mice.
[0016] A. Comparison of HE staining images of psoriasis-like lesions in mice; B. Comparison of Ki67 expression images of immunohistochemistry in psoriasis-like lesions in mice; C. Ki67 expression index of psoriasis-like lesions in mice; D E. TCR fluorescence of psoriasis-like lesions in mice
[0017] *P<0.05, ***P<0.001; Ctrl is the control group.
[0018] Figure 3 , hydrogen intervention can inhibit IL-23-induced oxidative stress and inflammatory response.
[0019] * P<0.05, ** P<0.01 DETAILED DESCRIPTION
[0020] The present invention is further described below in conjunction with specific examples. It should be emphasized that these examples are only used to illustrate the present invention and are not used to limit the scope of the present invention. The main features of the present invention can be used in various embodiments without departing from the scope of the present invention. Unless otherwise defined, all professional and scientific terms have the same meaning as those familiar to those skilled in the art. In addition, any method and material similar or equivalent to the recorded content can be applied to the present invention, and these equivalents are considered to be within the scope of the present invention and are covered by the claims. The preferred implementation methods and materials described in the text are for demonstration purposes only.
[0021] Example 1. Hydrogen inhibits oxidative stress, inflammatory response and cell proliferation in keratinocytes isolated from psoriasis patients
[0022] Experimental materials and equipment:
[0023] Clinical skin specimens: Skin samples were collected from 3 psoriasis patients (diagnosed as progressive psoriasis vulgaris) at the outpatient clinic of the Ninth People's Hospital affiliated to Shanghai Jiaotong University, and 3 healthy people in Shanghai. Skin samples included epidermal cells and keratinocytes.
[0024] Serum-free keratinocyte culture medium (Gibco, Grand Island, NY)
[0025] 2%, 35% or 65% hydrogen incubator
[0026] TNF-α(100ng / ml)
[0027] IL-17A (100 ng / ml)
[0028] Dihydroethidium probe (DHE; Beyotime, Shanghai, China)
[0029] Fluorescence microscope (Olympus IX71)
[0030] Flow cytometry
[0031] ROS ELISA kit (J&L Bio., Shanghai, China)
[0032] Commercially available detection kit (Nanjing Jiancheng Biotechnology, Jiangsu, China)
[0033] Trizol reagent (Thermo Fisher Scientific)
[0034] Reverse transcription kit (TaKaRa)
[0035] Fluorescence quantitative PCR kit (TaKaRa)
[0036] BCA test kit (Beyotime, China)
[0037] 8% SDS-PAGE
[0038] Nitrocellulose membrane (Millipore, USA)
[0039] 5% skim milk
[0040] Specific primary and secondary antibodies
[0041] Bio-Rad imaging system (Bio-Rad, Hercules, California, USA).
[0042] Experimental methods:
[0043] Primary epidermal cells and human keratinocyte cell line (HaCaT) extracted from clinical specimens were cultured in serum-free keratinocyte medium (Gibco, Grand Island, NY). These cell lines were cultured in a 2%, 35%, or 65% hydrogen incubator for 24 hours and then treated with TNF-α (100 ng / ml) or IL-17A (100 ng / ml) for 4 hours or 48 hours. The ROS level in keratinocytes was detected using a dihydroethidium probe (DHE; Beyotime, Shanghai, China). Fluorescence images were collected using a fluorescence microscope (Olympus IX71), and the fluorescence intensity was measured by flow cytometry. The ROS level in the wound homogenate was detected using a ROS ELISA kit (J&L Bio., Shanghai, China). Malondialdehyde (MDA) and superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx) activities in keratinocytes and / or wound homogenates were measured using commercially available detection kits (Nanjing Jiancheng Biotechnology, Jiangsu, China). Quantitative real-time PCR and immunoblotting: Total RNA was isolated from keratinocytes and skin tissues using Trizol reagent (Thermo Fisher Scientific) and reverse transcribed using a reverse transcription kit (TaKaRa) according to the manufacturer's instructions. RT-PCR was then performed using a fluorescent quantitative PCR kit (TaKaRa), and gene expression was calculated using the 2-ΔΔCT formula. GAPDH was an internal reference for mRNA. Total protein was extracted from cell or tissue samples and quantified using a BCA detection kit (Beyotime, China). Equal amounts of protein were separated by 8% SDS-PAGE and then transferred to nitrocellulose membranes (Millipore, USA). The membranes were blocked with 5% skim milk for 1 h and detected with specific primary and secondary antibodies in sequence. Immunoblots were quantified by the Bio-Rad imaging system (Bio-Rad, Hercules, California, USA).
[0044] Experimental results:
[0045] The effects of hydrogen on oxidative and inflammatory levels in keratinocytes isolated from three patients with progressive psoriasis vulgaris and three healthy control subjects were evaluated.
[0046] The results are as follows Figure 1 As shown in Figure 2, compared with the healthy group, the levels of ROS and malondialdehyde (MDA, lipid peroxidation) in the psoriasis group were significantly increased (P < 0.01, Figure 1 A-1C). After 12 h of treatment with 65% hydrogen, the levels of ROS and MDA (oxidative stress) decreased significantly in the psoriasis group, but not in the healthy control group (P < 0.01, Figure 1At the same time, quantitative PCR further showed that hydrogen treatment also reduced the levels of upregulated inflammatory cytokines (such as IL-22, IL-23, IL-17, IL-6, and TNF-α) in the psoriasis group (P < 0.01, Figure 1 Similarly, treatment with 65% hydrogen for 12 h or 24 h could also inhibit the abnormal proliferation of keratinocytes in the psoriasis group (P < 0.01, Figure 1 I). These data suggest that hydrogen has potential antioxidant, anti-inflammatory, and antiproliferative effects on psoriatic keratinocytes.
[0047] Example 2. Inhalation of hydrogen gas alleviates IL-23-induced psoriasis-like lesions in mice
[0048] Experimental materials and equipment:
[0049] 8-10 weeks old C57BL / 6J mice (Changzhou Cavens Laboratory Animal Co., Ltd.)
[0050] IL-23 (1 μg), PBS solution, paraformaldehyde, hematoxylin and eosin, paraffin sections, 3% hydrogen O2, 10% goat serum, primary and secondary antibodies, DAB substrate-color change agent solution, 4% formalin fixative, 0.1% Triton X-100
[0051] p65 (Cell Signaling, 1:100)
[0052] Anti-rabbit secondary antibody (FITC, Sigma, 1:200)
[0053] Anti-phospholipid-p65 antibody (Cell Signaling, 1:200)
[0054] Ki67 (Cell Signaling, 1:100)
[0055] Alexa Fluor-conjugated secondary antibodies (Alexa Fluor 488, Mac3; Alexa Fluor 594 and 647, p16; Thermo Fisher Scientific)
[0056] MOWIOL 488 containing DAPI (Sigma-Aldrich)
[0057] Projector installed by Thermo Fisher Scientific.
[0058] A confocal laser scanning microscope (LSM 710; Carl Zeiss, Oberkochen, Germany) was used with a ×20 objective (Carl Zeiss).
[0059] DAPI, Alexa Fluor 488, Alexa Fluor 594, and Alexa Fluor 647, diode-pumped solid-state lasers at 405 nm, argon at 488 nm, and diode-pumped solid-state lasers at 561 nm and 633 nm.
[0060] Software: ImageJ, version 1.8.0.
[0061] Experimental methods:
[0062] The back skin of C57BL / 6J mice was shaved, and the mice were placed in a specific closed device to produce a mixed air including 2%, 35% or 65% hydrogen and 21% O2 for two weeks (6 hours per day). Thereafter, IL-23 (1 μg) or control (PBS) was intradermally injected into the shaved back skin of each mouse every day for 4 days. Mouse skin samples were excised 24 hours after the last IL-23 injection. The skin samples were fixed in paraformaldehyde and embedded in paraffin. Sections (6 μm thick) were stained with hematoxylin and eosin (HE) or processed for immunostaining. For immunohistochemistry, the deparaffinized sections were incubated with 3% hydrogen O2 to quench endogenous peroxidase. After blocking with 10% goat serum, the sections were incubated with the designated primary and secondary antibodies. The sections were visualized using DAB substrate-color change agent solution (Biocare Medical) and counterstained with HE. For p65 immunohistochemistry, cells were fixed with 4% formalin, permeabilized with 0.1% Triton X-100, and immunostained with p65 (Cell Signaling, 1:100) and anti-rabbit secondary antibody (FITC, Sigma, 1:200). Paraffin-embedded sections were stained with hematoxylin and eosin, antiphospholipid-p65 antibody (Cell Signaling, 1:200), or Ki67 (Cell Signaling, 1:100). For immunofluorescence, appropriate Alexa Fluor-conjugated secondary antibodies (Alexa Fluor 488, Mac3; Alexa Fluor 594 and 647, p16; Thermo Fisher Scientific) were used with a projector mounted with MOWIOL 488 (Sigma-Aldrich) (Thermo Fisher Scientific) containing DAPI. Images were taken on a confocal laser scanning microscope (LSM 710; Carl Zeiss, Oberkochen, Germany) equipped with a ×20 objective (Carl Zeiss). DAPI, Alexa Fluor 488, Alexa Fluor 594, and Alexa Fluor 647 were excited using a 405-nm diode, 488-nm argon, and 561-nm and 633-nm diode-pumped solid-state laser, respectively. The pinhole size of each laser was the same to achieve optimal fit. Mac3+ and p16+ cells were counted using ImageJ, version 1.8.0.
[0063] Experimental results:
[0064] The results are as follows Figure 2As shown, injection of IL-23 resulted in obvious psoriatic lesions on the back skin, characterized by erythematous swelling, accompanied by obvious acanthosis, hyperkeratosis, and lymphocytic infiltration ( Figure 2 A). Pretreatment with 35% and 65% hydrogen significantly alleviated IL-23-induced swelling and hyperkeratosis ( Figure 2 A). Immunohistochemical analysis further showed that the application of hydrogen significantly inhibited the IL-23-induced increase in Ki67 expression in psoriasis lesions, and a stronger effect was observed when a higher concentration of hydrogen was used for treatment ( Figure 2 B-2C). Immunofluorescence detection showed that 65% hydrogen treatment significantly reduced the infiltration of IL-23-stimulated dermal γδT cells (P < 0.01, Figure 2 D-2E).
[0065] Example 3. Hydrogen can significantly inhibit IL-23-induced oxidative stress and inflammatory response.
[0066] The experimental materials, equipment, and experimental methods refer to Example 2.
[0067] Experimental results:
[0068] 65% hydrogen treatment significantly abolished the IL-23-induced increase in ROS and MDA levels in psoriasis lesions ( Figure 3 A-3B). At the same time, quantitative PCR, immunoblotting and immunohistochemistry analysis further showed that the pro-inflammatory cytokines TNF-α, IL-22, IL-17A and IL-17F were significantly downregulated in the lesional skin of mice treated with 65% hydrogen, indicating that 65% hydrogen reduced the inflammatory response of psoriasis ( Figure 3 E-3H&3K). In addition, we evaluated the effect of hydrogen on NF-κB signaling, an important regulator in the pathogenesis of psoriasis, by immunoblotting and immunohistochemical analysis. Lesion skin tissues of psoriatic mice showed significantly enhanced expression and phosphorylation of p65 and IKBα (NF-κB pathway), while hydrogen treatment significantly downregulated their expression and phosphorylation in lesions ( Figure 3 I-3J&3L). These data suggest that hydrogen may alleviate IL-23-induced inflammation by inhibiting the activation of NF-κB.
Claims
1. Use of hydrogen for preparing a drug for preventing or treating psoriasis.
2. The use of hydrogen for preparing a drug for preventing or treating psoriasis according to claim 1, wherein the hydrogen is 65% hydrogen.
